Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REINFORCE
NCT07579195Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Aug 2026
- Primary completion
- Feb 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by University of Washington. Primary endpoint: Completion rate of protocol-defined treatment at 12 months. Started Aug 2026; status: recruiting.
Beyond the preview
Go deeper on NCT07579195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07579195.